Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.62 |
| ▸ | RAB9A | P51151 | 13/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | PKM | P14618 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | METAP2 | P50579 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | METAP1 | P53582 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941412 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30561047 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL172216 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30634854 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1272832 | 0.77 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31154260 | 0.77 | GAA (0.49) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4371289 | 0.77 | GAA (0.65) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17336302 | 0.77 | ALDH1A1 (0.61) | NPC1RAB9AKDM4EALDH1A1PKM | |
| Water SCHEMBL9817804 | 0.76 | NPC1 (0.95) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31509605 | 0.76 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| CN-106810539-A | A kind of phenyl bridged pyrazolate base benzimidizole derivatives and preparation method thereof | 中国科学院大连化学物理研究所 | 2017-06-09 | — | — | CN | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| CN-1308250-A | Photographic material, compound and method | EASTMAN KODAK CO (US) | 2001-08-15 | — | — | CN | disclosed |
| CN-1235280-A | Photographic element containing yellow dye-forming photographic coupler | EASTMAN KODAK CO (US) | 1999-11-17 | — | — | CN | disclosed |
| CN-86104070-A | LIGHT-SENSITIVE SILVER HALIDE PHOTOGRAPHIC MATERIAL | — | 1986-12-24 | — | — | CN | disclosed |
| US-4027032-A | Combating heminthosporium fungi with 2-[3',5'-dimethylpyrazolyl-(1')]-benzimidazole | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
| US-3839575-A | 2-(PYRAZOLYL-(1))-BENZIMIDAZOLE FUNGICIDAL,AND BACTERICIDAL AGENTS | BAYER AG | 1974-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | NPC1 3302/4885RAB9A 810/4885SMN1; SMN2 4210/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | NPC1 2551/4885RAB9A 955/4885SMN1; SMN2 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.